Progress On Reducing Child Mortality

Global mortality rates and deaths by age

- Children under age 5
- Neonatal
- Children and young adolescents aged 5–14

Mortality rate (probability of dying per 1,000)

Year | 1990 | 2000 | 2017
---|---|---|---
Under-five | 12.6 million | 9.8 million | 5.4 million
Neonatal deaths | 5.0 million | 4.0 million | 2.5 million
40% of under-five deaths | 41% of under-five deaths | 47% of under-five deaths
Children and young adolescents aged 5–14 | 1.7 million | 1.4 million | 0.9 million

Engaging with Partners: Key Strategy for Success to Date

**PROCUREMENT & MARKET SHAPING**

*Suppliers*
- Gavi, the Vaccine Alliance
- Bill & Melinda Gates Foundation
- WHO
- MSF
- CEPI

**SUPPLY PLANNING & COORDINATION**

*Suppliers*
- Measles & Rubella Initiative (MRI)
- GPEI / IMG
- Country coordination International Coordination Group (ICG)

**COUNTRY SUPPORT & SUSTAINABILITY**

*Suppliers*
- Country support Gavi Partnership Engagement Framework (PEF)

**GAVI CO-FINANCING**

Gavi’s co-financing policy aims to further strengthen ownership and long-term sustainability.
How we have work with businesses and industries

- **Targeted bilateral engagement with companies** including at Executive/President-level to establish positive relationships, and to discuss strategic issues including to influence of R&D pipelines.

- Regular **engagement with industry associations** (e.g. IFPMA, DCVMMN) for pan-industry reach and to understand industry trends.

- **Convenes the industry-wide forums by segment/product group** on a (bi)annual basis for dialogues on strategic direction, to understand supplier challenges and market perspectives.

- These bring together **>1000 participants** across ~20 industry meetings per year.

- Various interaction with industry are based on **fairness, transparency**, while at the same time ensuring **confidentiality** of commercially sensitive information.

- **Publishes strategic market information** (e.g. market analyses, demand/supply volumes, pricing, procurement plans, etc.) to **reduce market information asymmetries** ultimately to improve market functioning.

### 2018 Industry Meetings

<table>
<thead>
<tr>
<th>Centre</th>
<th>Industry Consultation</th>
<th>Pre-tender Meeting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Health Technologies Centre</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Medicines &amp; Nutrition Centre</td>
<td>4</td>
<td>6</td>
</tr>
<tr>
<td>Vaccines Centre</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Water, Sanitation &amp; Education Centre</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Other Centres</td>
<td>2</td>
<td>1</td>
</tr>
</tbody>
</table>

- (1) HIV diagnostics, (2) Zika diagnostics, (3) Cold Chain Equip Medicinal Products across industry Portfolio of vaccines across industry Sanitation Products (Regional industry consultations)

- (1) Unmanned Aerial Vehicles (UAVs) (2) Household Water Treatment
Global targets to further reduce Child Mortality (per 1,000 live birth)

Targeted reduction in Under 5 and Neonatal mortality rates, Global

Report 2018
UN Inter-agency Group for Child Mortality Estimation UNICEF-WHO-WB-UN
Influence global and local markets – breaking down market barriers that inhibit children’s access to essential supplies.

Deepen our private-sector partnerships, understanding their core businesses, innovation and advocacy to improve children’s lives.

Pursue a research and development pipeline of vaccines, medicines and technologies to drive progress for children.

1. Programming for at-scale results for children (Cross-sectoral programming; Systems strengthening and service delivery; Humanitarian and development integration; Community dialogue and behaviour change; South-south and triangular cooperation; Human rights-based approach)

2. Gender-responsive programming (Gender-responsive programming)

3. Winning support for the cause of children from decision makers and the wider public (Advocacy, public engagement, communication and movements; Children as change agents)

4. Developing and leveraging resources and partnerships for children (Leveraging resources for children; Resource mobilization and fundraising)

5. Harnessing the power of business and markets for children (Leveraging private sector/corporate partnerships; Market shaping)

6. United Nations working together (Strengthened collaboration with other UN entities; Strengthened contribution to system-wide coherence)

7. Fostering innovations in programming and advocacy processes and practices (Promote the use of new technologies)

8. Harnessing the power of evidence as a driver of change for children (Evaluations, research and data)
A Products and Markets Futures

UNICEF outcome areas and results

- **Scale-up of core programmes**
- **New products, services, and markets, including local**
- **Service delivery modes, including self procurement**

NB: Illustration. Size of bubbles denotes the potential impact should goals/targets be achieved. All information subjectively estimated. Subset (~40%) of all P&M futures targets.

- Requires different planning horizon for complex product and market challenges that have long lead times
- Demands new ways of working to influence markets where UNICEF does not routinely procure
- Necessitates executive-level supplier engagement to foster strategic dialogue and influence suppliers’ priorities
- Involves looking beyond UNICEF’s core programming focus today to meet the needs of children and youth tomorrow (e.g. in diabetes, cancer, mental health)
- Offers opportunities to foster economic and social development through new market goals

NB: Illustration. Size of bubbles denotes the potential impact should goals/targets be achieved. All information subjectively estimated. Subset (~40%) of all P&M futures targets.
## Identifying innovations to accelerate results for children

<table>
<thead>
<tr>
<th>SP Goal</th>
<th>Accelerator / innovation</th>
<th>Reach</th>
<th>Timeline to market</th>
<th>Difficulty</th>
<th>Impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Vaccines: Ebola/Marburg, Zika, Dengue, Malaria</td>
<td></td>
<td>by 2019</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>HIV Vaccine</td>
<td></td>
<td>by 2021</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>MERS Vaccine</td>
<td></td>
<td>by 2030</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Injectable ART for adolescents with HIV/AIDS to increase adherence</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Improved vector controls technologies: mosquitos, etc.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Single pill treatment for diabetes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Rapid diagnostics for fevers, pneumonia, e. Coli, cholera, zika-dengue-chikungunya, etc.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Triplex rapid test for HIV/syphilis/Hepatitis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Chickpea and soya based RUTF</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Oxygen therapy – pulse oximetry and oxygen supply</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Affordable Hep C treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Affordable pediatric oncology treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Next generation / novel pediatrics: antimalarial, antibiotics (AMR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>New science / improved vaccines: Yellow Fever, Mening,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Vaccine fill-and-finish in Africa</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Digital ways to support mothers from pregnancy through 1000 days</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Adolescent mental health medicines</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Adolesc. mental health: e.g. fb algorithm to detect depression, bullying, when support is needed</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>A.I for health planning (theory of change, bottlenecks)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>A.I. to be predictive on health, well being of adolescents</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Point of care ultrasound diag., cervical pessaries, fetal heart rate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Biomarkers for early diagnosis of stunting</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>HIV self test</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Reach:**
- Universal
- > 50 countries
- < 50 countries

**Timeline to market:**
- by 2019
- by 2021
- by 2030

**Difficulty source:**
- Market issue
- Being developed
- Discovery needed

**Impact on a SDG or SP result target:**
- Transform
- Contribute
- Enable
Illustration of targets for immunization products (vaccines and related devices)

NB: Illustration. Size of bubbles denotes the potential impact should goals/targets be achieved. All information subjectively estimated.
The **Healthy Market Framework** is a set of attributes to measure the health of a market, and product-specific process to assess markets value.

<table>
<thead>
<tr>
<th>1. Supply meets demand</th>
<th>2. Accommodate country product preferences &amp; affordability</th>
</tr>
</thead>
<tbody>
<tr>
<td>3. Back-up supply capacity</td>
<td>4. Individual supplier risk</td>
</tr>
<tr>
<td>5. QA risk</td>
<td>6. Long term competition</td>
</tr>
<tr>
<td>7. Diverse and local mfg base</td>
<td>8. Product innovation</td>
</tr>
</tbody>
</table>

---

### Inadequate supply

Markets that do not meet demand are not healthy.

Second building block is basic affordability and that country preferences (presentation, language, etc.) can be met.

Next tier reflects risks that can be addressed by procurement tactics & other interventions.

Final tier addresses longer term achievements and sustainability.

- Foundational building block of a healthy market is supply meets demand.
- Moving beyond ‘traditional’ competition….
UNICEF engagement with industry: pre-licensure

Vaccine developers
- Universities
- Institutes
- Small & Midsized Entities (SMEs)
- MNC
- Developing Country Vaccine Manufacturers (DCVMN)

Vaccine Manufacturers
- Small & Midsized Entities (SMEs)
- MNC
- Developing Country Vaccine Manufacturers (DCVMN)

Experimental phase

Research phase
- Preclinical testing

Development Phase
- Phase I safety/ POC
- Phase II Dose/ safety
- Phase III Efficacy/ Safety

Registration Phase
- Regulatory approval

Production phase
- Bulk production filling
- Packaging/ batch release

QC/ cGMP Scale up manufacturing

Field Studies and Emergency response Prelicensure

Field Studies and Emergency response Post licensure
Priorities in our Partnerships and Strategic Engagements

• Improved access to vaccines for all children: addressing inequities of Vaccine Introduction in MICs through improved availability of affordable supply (e.g. PCV, Rota, HPV other new vaccines) DCVMs.

• Improved sustainability and long-term supply security, with increased sourcing from DCVMs, especially for those commodities which are currently in shortage to meet increasing demands (IPV, Rota, HPV)

• Further sensitizing our procurement processes to ensure and motivate research and development and product innovation

Through:
Re-orienting our procurement function to engage with the entire ecosystem

High-level partnership to influence private sector’s investments to ensure availability of products that meet the needs and value for children, especially for the most vulnerable populations where access is limited